<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="alport" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">alport</book-part-id>
      <title-group>
        <title>Alport Syndrome and Thin Basement Membrane Nephropathy</title>
        <alt-title alt-title-type="alt-title">Synonyms: Alport Syndrome and Benign Familial Hematuria, Alport Syndrome and Thin Basement Membrane Disease</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kashtan</surname>
            <given-names>Clifford E</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Pediatrics <break/>University of Minnesota <break/>Minneapolis, Minnesota</aff>
          <email>kasht001@tc.umn.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>28</day>
          <month>8</month>
          <year>2001</year>
        </date>
        <date date-type="updated">
          <day>25</day>
          <month>11</month>
          <year>2015</year>
        </date>
        <date date-type="revised">
          <day>8</day>
          <month>1</month>
          <year>2008</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="alpha1-a" document-type="chapter">Alpha-1 Antitrypsin Deficiency</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="alstrom" document-type="chapter">Alstr&#x000f6;m Syndrome</related-object>
      <abstract id="alport.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Alport syndrome (AS) is characterized by renal, cochlear, and ocular involvement. In the absence of treatment, renal disease progresses from microscopic hematuria to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with X-linked (XL) AS, and in all males and females with autosomal recessive (AR) AS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with autosomal dominant (AD) AS, ESRD is frequently delayed until later adulthood, SNHL is also relatively late in onset and ocular involvement is rare.</p>
          <p>Thin basement membrane nephropathy (TBMN) is characterized by persistent microscopic hematuria often first observed in childhood; progressive renal disease is relatively unusual and extrarenal abnormalities are rare.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of Alport syndrome and thin basement membrane nephropathy rests on:</p>
          <list list-type="bullet">
            <list-item>
              <p>History and physical examination, which may include audiologic, renal, and ophthalmic evaluation;</p>
            </list-item>
            <list-item>
              <p>Detailed family history and possibly urinalyses on first- and second-degree relatives;</p>
            </list-item>
            <list-item>
              <p>Immunohistochemical analysis of basement membrane type IV collagen expression, using skin and/or renal biopsy specimens; and</p>
            </list-item>
            <list-item>
              <p>Examination of renal biopsy specimens by electron microscopy.</p>
            </list-item>
          </list>
          <p>With these tools, the diagnosis can be confirmed in most cases. AS and many cases of TBMN are caused by mutation of the type IV collagen genes <italic toggle="yes">COL4A3</italic>, <italic toggle="yes">COL4A4</italic>, and <italic toggle="yes">COL4A5.</italic></p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Alport syndrome: angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker in proteinuric individuals; potential living related donors must be evaluated carefully to avoid nephrectomy in an affected individual. Routine treatment of hypertension; renal transplantation for ESRD. Routine treatment of SNHL and cataracts; surgical intervention for symptomatic leiomyomas.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Protect corneas of those with recurrent corneal erosions from minor trauma. Minimize exposure to loud noise.</p>
          <p><italic toggle="yes">Surveillance</italic>: Follow up of all individuals with Alport syndrome and thin basement membrane nephropathy with a nephrologist; monitoring of females with XLAS with measurement of blood pressure and renal function; audiologic evaluation of children with Alport syndrome every one to two years beginning at age six to seven years; monitoring of transplant recipients for development of anti-glomerular basement membrane antibody-mediated glomerulonephritis.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Evaluate at-risk family members either by urinalysis or, if the pathogenic variant(s) in the family are known, by molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Three modes of inheritance are recognized for Alport syndrome: X-linked, autosomal recessive, and autosomal dominant. Currently, TBMN is known to be inherited in an autosomal dominant manner only.</p>
          <list list-type="bullet">
            <list-item>
              <p>In families with X-linked inheritance, mothers heterozygous for a <italic toggle="yes">COL4A5</italic> pathogenic variant have a 50% chance of transmitting the pathogenic variant in each pregnancy; sons who inherit the pathogenic variant will be affected with Alport syndrome and will eventually develop ESRD and, in most cases, deafness; daughters who inherit the pathogenic variant will typically have asymptomatic hematuria but may have more severe renal disease. Affected males will pass the pathogenic variant to all of their daughters and none of their sons.</p>
            </list-item>
            <list-item>
              <p>In families with autosomal recessive inheritance, the parents of an affected child are obligate heterozygotes and carry one mutant allele; at conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier who may or may not be symptomatic, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>In families with autosomal dominant inheritance, each child of an affected individual has a 50% chance of inheriting the pathogenic variant and having a collagen IV disorder (autosomal dominant AS or TBMN).</p>
            </list-item>
          </list>
          <p>Molecular genetic testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant(s) in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="alport.Diagnosis">
        <title>Diagnosis</title>
        <p>Pathogenic variants in <italic toggle="yes">COL4A3</italic>, <italic toggle="yes">COL4A4</italic>, or <italic toggle="yes">COL4A5</italic> result in a spectrum of phenotypes from Alport syndrome to thin basement membrane nephropathy (TBMN) [<xref ref-type="bibr" rid="alport.REF.longo.2002.1947">Longo et al 2002</xref>], including X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS), or autosomal dominant collagen IV disorders (autosomal dominant Alport syndrome [ADAS] and TBMN).</p>
        <sec id="alport.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Alport syndrome <bold>should be suspected</bold> in an individual with the following clinical and pedigree features [<xref ref-type="bibr" rid="alport.REF.kashtan.2004.1290">Kashtan 2004</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Renal</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Hematuria. In XLAS, 100% of affected males and more than 90% of affected females have microhematuria; 100% of males and females with ARAS have hematuria. Episodic gross hematuria is not unusual.</p>
                </list-item>
                <list-item>
                  <p>Proteinuria, hypertension, and renal insufficiency develop with advancing age in all males with XLAS, and in all males and females with ARAS.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Cochlear</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Bilateral high-frequency sensorineural hearing loss (SNHL) typically becomes apparent by audiometry in late childhood or early adolescence in males with XLAS and in males and females with ARAS.</p>
                </list-item>
                <list-item>
                  <p>In XLAS, SNHL eventually develops in 80%-90% of affected males as well as in some affected females; the incidence of SNHL in males and females with ARAS is probably similar to the incidence in males with XLAS.</p>
                </list-item>
                <list-item>
                  <p>In some families with XLAS and in ADAS, SNHL may not be detectable until well into adulthood.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Ocular</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Anterior lenticonus is pathognomonic of Alport syndrome. It occurs in 15%-20% of those with XLAS or ARAS and typically becomes apparent in late adolescence or early adulthood.</p>
                </list-item>
                <list-item>
                  <p>Perimacular flecks occur in approximately 30% of individuals with Alport syndrome.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Family history</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Family history positive for hematuria, deafness, and/or end stage renal disease is frequently seen.</p>
                </list-item>
                <list-item>
                  <p>Family history of hematuria or renal failure may be negative because 10%-15% of males with XLAS have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant and approximately 15% of affected individuals have ARAS.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>TBMN <bold>should be suspected</bold> in an individual with the following clinical and pedigree features [<xref ref-type="bibr" rid="alport.REF.kashtan.2004.1290">Kashtan 2004</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Persistent hematuria without proteinuria</p>
            </list-item>
            <list-item>
              <p>Family history:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Negative for renal failure</p>
                </list-item>
                <list-item>
                  <p>Positive for hematuria</p>
                  <p>Note: Criterion may not be reliable because individuals eventually diagnosed as having TBMN are frequently unaware that they have relatives with hematuria.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: An individual suspected of having Alport syndrome or TBMN should be evaluated by either a pediatric or adult nephrologist (depending on age).</p>
        </sec>
        <sec id="alport.Testing">
          <title>Testing</title>
          <sec id="alport.Urinalysis">
            <title>Urinalysis</title>
            <p><bold>Males with XLAS; males and females with ARAS.</bold> Urinalysis typically shows hematuria (dozens to hundreds of erythrocytes per high-power microscope field). Overlap with normal results is minimal.</p>
            <p><bold>Female heterozygotes for XLAS.</bold> Approximately 95% of heterozygotes exhibit persistent or intermittent microhematuria (blood in the urine detectable only by microscope).</p>
            <p><bold>Both males and females with XLAS</bold> may have intermittent or constant gross hematuria.</p>
            <p><bold>Heterozygotes for ARAS.</bold> Approximately 50% of carriers of ARAS exhibit persistent or intermittent microhematuria.</p>
            <p><bold>Individuals with ADAS and TBMN.</bold> Urinalysis shows microscopic hematuria.</p>
          </sec>
          <sec id="alport.Immunohistochemical_Analysis_of_B">
            <title>Immunohistochemical Analysis of Basement Membrane Type IV Collagen Expression</title>
            <p>
              <bold>Skin biopsy</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Males with XLAS.</bold> In about 80% of males, incubation of a skin biopsy specimen with a monoclonal antibody directed against the collagen &#x003b1;5(IV) chain shows complete absence of staining of epidermal basement membranes. Approximately 20% of males show normal staining.</p>
              </list-item>
              <list-item>
                <p><bold>Females heterozygous for XLAS.</bold> Approximately 60%-70% of heterozygous females exhibit discontinuous staining of the collagen &#x003b1;5(IV) chain [<xref ref-type="bibr" rid="alport.REF.van_der_loop.1999.1217">van der Loop et al 1999</xref>]. This is attributed to X-chromosome inactivation, by which it would be expected that one half of the basilar keratinocytes would express a normal collagen &#x003b1;5(IV) chain.</p>
              </list-item>
              <list-item>
                <p><bold>Individuals with ARAS.</bold> All individuals have normal skin reactivity for the collagen &#x003b1;5(IV) chain.</p>
              </list-item>
              <list-item>
                <p><bold>Individuals with ADAS and TBMN.</bold> All individuals have normal skin reactivity for the collagen &#x003b1;5(IV) chain.</p>
              </list-item>
            </list>
            <p>
              <bold>Renal biopsy</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Males with XLAS</bold> typically show complete absence of immunostaining for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain on renal biopsy.</p>
                <p>Approximately 20% of males with XLAS show normal staining of renal basement membranes for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain.</p>
              </list-item>
              <list-item>
                <p><bold>Females heterozygous for XLAS</bold> typically exhibit patchy loss of staining for the collagen &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains in GBMs and tubular basement membranes [<xref ref-type="bibr" rid="alport.REF.kashtan.1996.142">Kashtan et al 1996</xref>]. Some heterozygous females exhibit normal staining for the collagen &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains in renal basement membranes.</p>
              </list-item>
              <list-item>
                <p><bold>Individuals with ARAS</bold> show abnormalities of renal type IV collagen expression that differ from those of individuals with X-linked disease. Individuals with ARAS typically exhibit complete absence of staining for the collagen &#x003b1;3(IV) chain and &#x003b1;4(IV) chain. However, whereas their GBMs show no staining for the collagen &#x003b1;5(IV) chain, staining of Bowman's capsules and tubular basement membranes for the collagen &#x003b1;5(IV) chain is positive [<xref ref-type="bibr" rid="alport.REF.gubler.1995.1142">Gubler et al 1995</xref>]. Some individuals with ARAS exhibit normal renal basement membrane staining for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain.</p>
              </list-item>
              <list-item>
                <p><bold>Individuals with ADAS and TBMN</bold> exhibit normal GBM staining for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain.</p>
              </list-item>
            </list>
            <p>
              <bold>Electron microscopy (EM)</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Normal.</bold> The normal glomerular capillary wall has a trilaminar appearance consisting of a homogeneous electron-dense layer (lamina densa) sandwiched between two electron-lucent layers (the laminae rara interna and externa).</p>
                <p>The outer (subepithelial) aspect of the glomerular capillary wall, where it abuts the foot processes of the glomerular visceral epithelial cells, is smooth and regular.</p>
                <p>A variety of techniques have been used to measure GBM width. The cut-off value in adults ranges from 250 nm to 330 nm, depending on technique. The cut-off value in children ranges from 200 nm to 250 nm, depending on technique (250 nm is within 2 SD of the mean at age 11 years).</p>
              </list-item>
              <list-item>
                <p><bold>Alport syndrome.</bold> When diffusely present, the following three alterations are pathognomonic of Alport syndrome:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>The lamina densa appears to be split into multiple interlacing strands of electron-dense material, resembling basket-weaving.</p>
                  </list-item>
                  <list-item>
                    <p>The lacunae between these strands are frequently occupied by round, electron-dense bodies (possibly entrapped cytoplasm).</p>
                  </list-item>
                  <list-item>
                    <p>The glomerular capillary wall is diffusely thickened and its epithelial aspect is scalloped.</p>
                  </list-item>
                </list>
                <p>However, the earliest change in Alport syndrome is diffuse thinning of the glomerular capillary wall; thus, electron microscopy alone may not always be sufficient to differentiate Alport syndrome from thin basement membrane disease. (Marked variability in GBM width within a glomerulus in an individual with persistent microhematuria should raise suspicion of Alport syndrome.)</p>
              </list-item>
              <list-item>
                <p><bold>TBMN.</bold> Most individuals with TBMN exhibit diffuse thinning of the lamina densa and of the GBM as a whole. The intraglomerular variability in GBM width is small in individuals with TBMN [<xref ref-type="bibr" rid="alport.REF.tiebosch.1989.14">Tiebosch et al 1989</xref>] and the GBM of individuals with TBMN remains attenuated over time, rather than undergoing the progressive thickening and multilamellation that is pathognomonic of Alport syndrome.</p>
                <p>Light and immunofluorescence microscopy are unremarkable in individuals with typical TBMN.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="alport.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of Alport syndrome and thin basement membrane nephropathy (TBMN) <bold>is established</bold> in a proband with identification of pathogenic variant(s) in one of the genes listed in <xref ref-type="table" rid="alport.T.molecular_genetic_testing_used">Table 1</xref>.</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <p><bold>Single-gene testing.</bold> Sequence analysis is performed first followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found.</p>
          <p>The choice of which of the three genes to test first is based on family history, clinical findings, histopathology, and frequencies of Alport syndrome and thin basement membrane nephropathy.</p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Alport syndrome</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Individuals with an X-linked family history (XLAS), test <italic toggle="yes">COL4A5</italic> first.</p>
                </list-item>
                <list-item>
                  <p>With a family history of either autosomal dominant or autosomal recessive inheritance, test <italic toggle="yes">COL4A3</italic> first, followed by <italic toggle="yes">COL4A4.</italic></p>
                </list-item>
                <list-item>
                  <p>In those who do not have a family history of a similarly affected relative, test <italic toggle="yes">COL4A5</italic> first, followed by <italic toggle="yes">COL4A3</italic> and <italic toggle="yes">COL4A4</italic></p>
                </list-item>
                <list-item>
                  <p>In some individuals with a negative family history, only a single variant may be found in either <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic>. In such cases it may be difficult for the clinician to determine if the patient has a <italic toggle="yes">de novo</italic> dominant variant or a single autosomal recessive variant (with the other variant perhaps not detectable on today&#x02019;s testing). In distinguishing between these two possibilities, note that a second undetected pathogenic variant in the proband is likely if:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>A parent has the pathogenic variant, but is asymptomatic or has only hematuria;</p>
                    </list-item>
                    <list-item>
                      <p>A young individual has proteinuria and decreased renal function, deafness, anterior lenticonus, or perimacular flecks;</p>
                    </list-item>
                    <list-item>
                      <p>An individual has abnormal collagen IV immunostaining in a renal biopsy specimen.</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>TBMN.</bold> Test <italic toggle="yes">COL4A3</italic> and <italic toggle="yes">COL4A4</italic>.</p>
            </list-item>
          </list>
          <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">COL4A5, COL4A3, COL4A4,</italic> and other genes of interest (see <xref ref-type="sec" rid="alport.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered and is the preferred methodology in many centers. Note: The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time.</p>
          <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
          <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing, mitochondrial sequencing, and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of Alport syndrome or thin basement membrane nephropathy. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene that results in a similar clinical presentation).</p>
          <p>For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
          <table-wrap id="alport.T.molecular_genetic_testing_used" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Alport Syndrome (AS)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of AS Attributed to Mutation of This Gene</th>
                  <th id="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mode of Inheritance</th>
                  <th id="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">COL4A5</italic>
                  </td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">65%&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">X-linked</td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_4" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6,&#x000a0;7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1"><italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic></td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">15%&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Autosomal recessive</td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3,&#x000a0;8</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_4" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6,&#x000a0;9</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1"><italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic></td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">20%&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Autosomal dominant</td>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_4" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6,&#x000a0;9</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="alport.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="alport" object-id="alport.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="alport.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="alport.TF.1.2">
                <label>2. </label>
                <p><xref ref-type="bibr" rid="alport.REF.fallerini.2014.252">Fallerini et al [2014]</xref>, <xref ref-type="bibr" rid="alport.REF.morini_re.2014.2740">Morini&#x000e8;re et al [2014]</xref>, <xref ref-type="bibr" rid="alport.REF.hertz.2015">Hertz et al [2015]</xref></p>
              </fn>
              <fn id="alport.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="alport.TF.1.4">
                <label>4. </label>
                <p>Some laboratories may offer targeted analysis for pathogenic variants which may vary by laboratory. The pathogenic variants <xref ref-type="table" rid="alport.T.summary_of_molecular_genetic_te">c.4692G&#x0003e;A</xref>, <xref ref-type="table" rid="alport.T.summary_of_molecular_genetic_te">c.4946T&#x0003e;G</xref>, and <xref ref-type="table" rid="alport.T.summary_of_molecular_genetic_te">c.5030G&#x0003e;A</xref> are particularly common in the United States.</p>
              </fn>
              <fn id="alport.TF.1.5">
                <label>5. </label>
                <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.</p>
              </fn>
              <fn id="alport.TF.1.6">
                <label>6. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="alport.TF.1.7">
                <label>7. </label>
                <p>Typically multiexon deletions occur in approximately 10% of females whose family history is consistent with X-linked inheritance [<xref ref-type="bibr" rid="alport.REF.jais.2003.2603">Jais et al 2003</xref>, <xref ref-type="bibr" rid="alport.REF.king.2006.1061">King et al 2006</xref>]. Multiexon duplications have also been reported [<xref ref-type="bibr" rid="alport.REF.arrondel.2004.2030">Arrondel et al 2004</xref>].</p>
              </fn>
              <fn id="alport.TF.1.8">
                <label>8. </label>
                <p>Detects 100% of individuals with ARAS with typical clinical findings and consanguineous parents [<xref ref-type="bibr" rid="alport.REF.nagel.2005.60">Nagel et al 2005</xref>]</p>
              </fn>
              <fn id="alport.TF.1.9">
                <label>9. </label>
                <p>The frequency of del/dup pathogenic variants in this disorder is unknown (i.e., no data on gene-targeted del/dup analysis are available).</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <table-wrap id="alport.T.summary_of_molecular_genetic_te" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Thin Basement Membrane Nephropathy (TBMN)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of TBMN Attributed to Mutation of This Gene</th>
                  <th id="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mode of Inheritance</th>
                  <th id="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">COL4A3</italic>
                  </td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">Unknown&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Autosomal dominant</td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_4" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Gene-targeted deletion/duplication analysis <sup>4,&#x000a0;5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">COL4A4</italic>
                  </td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">Unknown&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Autosomal dominant</td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_4" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Gene-targeted deletion/duplication analysis <sup>4,&#x000a0;5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_alport.T.summary_of_molecular_genetic_te_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="alport.TF.2.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="alport" object-id="alport.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="alport.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="alport.TF.2.2">
                <label>2. </label>
                <p>Many individuals with autosomal dominant TBMN (precise % unknown) have heterozygous pathogenic variants in <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> [<xref ref-type="bibr" rid="alport.REF.lemmink.1996.1114">Lemmink et al 1996</xref>, <xref ref-type="bibr" rid="alport.REF.boye.1998.1329">Boye et al 1998</xref>, <xref ref-type="bibr" rid="alport.REF.heidet.2001.97">Heidet et al 2001</xref>, <xref ref-type="bibr" rid="alport.REF.badenas.2002.1248">Badenas et al 2002</xref>, <xref ref-type="bibr" rid="alport.REF.buzza.2003.447">Buzza et al 2003</xref>].</p>
              </fn>
              <fn id="alport.TF.2.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="alport.TF.2.4">
                <label>4. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="alport.TF.2.5">
                <label>5. </label>
                <p>The frequency of del/dup pathogenic variants in this disorder is unknown (i.e., no data on gene-targeted del/dup analysis are available).</p>
              </fn>
              <fn id="alport.TF.2.6">
                <label>6. </label>
                <p>Linkage to <italic toggle="yes">COL4A3</italic> and <italic toggle="yes">COL4A4</italic> has been excluded in some families with TBMD, indicating that TBMD is a genetically heterogeneous condition [<xref ref-type="bibr" rid="alport.REF.piccini.1999.464">Piccini et al 1999</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Digenic inheritance.</bold>
<xref ref-type="bibr" rid="alport.REF.mencarelli.2015.163">Mencarelli et al [2015]</xref> have described digenic inheritance of Alport syndrome in several families. The causative allelic variants may be <italic toggle="yes">in</italic>
<italic toggle="yes">cis</italic> or <italic toggle="yes">in trans</italic>, and result in variable clinical features and transmission patterns.</p>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v23/n9/full/ejhg2014254a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="alport.REF.hertz.2015">Hertz et al 2015</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="alport.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="alport.Clinical_Description">
          <title>Clinical Description</title>
          <p>In Alport syndrome and thin basement membrane nephropathy (TBMN), a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities (Alport syndrome) to isolated hematuria with a typically benign course (TBMN) is observed.</p>
          <sec id="alport.Alport_Syndrome">
            <title>Alport Syndrome</title>
            <p>Alport syndrome has renal, cochlear, and ocular manifestations. Approximately 80% of Alport syndrome is X-linked; approximately 15% is autosomal recessive, and approximately 5% is autosomal dominant. Because Alport syndrome is predominantly an X-linked disorder, these manifestations are typically more severe in affected males. However, affected females with either XLAS or ARAS may have severe involvement as well. ADAS is typically a slowly progressive disorder; renal insufficiency and sensorineural hearing loss (SNHL) may not develop until relatively late in life.</p>
            <p><bold>Renal.</bold> The hallmark of Alport syndrome is microscopic hematuria (microhematuria). Males with XLAS have persistent microhematuria from early in life. Episodic gross hematuria can occur, especially during childhood. More than 90% of females with XLAS have microscopic hematuria, although it may be intermittent. Individuals with ARAS have persistent microhematuria, with no gender difference. Heterozygous carriers of a <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> pathogenic variant associated with ARAS have an estimated 50% incidence of persistent or intermittent microhematuria.</p>
            <p>All males with XLAS develop proteinuria and, eventually, progressive renal insufficiency, which leads to end-stage renal disease (ESRD). Overall, an estimated 60% reach ESRD by age 30 years, and 90% by age 40 years [<xref ref-type="bibr" rid="alport.REF.jais.2000.649">Jais et al 2000</xref>]. The rate of progression to ESRD is influenced by the nature of the <italic toggle="yes">COL4A5</italic> pathogenic variant (see <xref ref-type="sec" rid="alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</xref>).</p>
            <p>Approximately 12% of females with XLAS develop ESRD before age 40 years, increasing to 30% by age 60 years and 40% by age 80 years [<xref ref-type="bibr" rid="alport.REF.jais.2003.2603">Jais et al 2003</xref>].</p>
            <p>Most individuals with ARAS develop significant proteinuria in late childhood or early adolescence and ESRD before age 30 years. Progression to ESRD occurs at a slower pace in individuals with ADAS (frequently delayed until later adulthood) than in those with XLAS or ARAS.</p>
            <p><bold>Cochlear.</bold> Hearing loss in Alport syndrome is never congenital. Diminished hearing is usually detectable by late childhood or early adolescence in boys with XLAS. In its early stages, the hearing deficit is detectable only by audiometry, with bilateral reduction in sensitivity to tones in the 2000- to 8000-Hz range. In affected males, the hearing loss is progressive and eventually extends to other frequencies, including those of conversational speech. Hearing loss is frequently identifiable by formal assessment of hearing in late childhood, but in some families is not detectable until relatively late in life.</p>
            <p>SNHL develops in 80%-90% of males with XLAS by age 40 years [<xref ref-type="bibr" rid="alport.REF.jais.2000.649">Jais et al 2000</xref>]. The course of the hearing loss depends on the pathogenic variant (see <xref ref-type="sec" rid="alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</xref>). Hearing impairment in members of families with Alport syndrome is always accompanied by evidence of renal involvement; no convincing evidence that deaf males lacking renal disease can transmit Alport syndrome to their offspring has been reported. In females with XLAS, hearing loss is less frequent and tends to occur later in life.</p>
            <p>There do not appear to be gender differences in the incidence or course of hearing loss in ARAS. Individuals with ARAS typically exhibit juvenile onset of hearing loss. Hearing loss may be a very late development in individuals with ADAS.</p>
            <p>A histologic study of cochleas in individuals with Alport syndrome suggests that defective adhesion of the organ of Corti to the basilar membrane may underlie the hearing deficit [<xref ref-type="bibr" rid="alport.REF.merchant.2004.1609">Merchant et al 2004</xref>].</p>
            <p><bold>Ocular.</bold> Ocular lesions are common in Alport syndrome, occurring in 30%-40% of individuals with XLAS. The spectrum of ocular lesions appears to be similar in XLAS and ARAS. Ocular lesions appear to be relatively uncommon in ADAS.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Anterior lenticonus,</bold> in which the central portion of the lens protrudes into the anterior chamber, is virtually pathognomonic in Alport syndrome. When present, anterior lenticonus is bilateral in approximately 75% of individuals. It is absent at birth, usually appearing during the second to third decade of life. Progressive distortion of the lens may occur, accompanied by increasing myopia. Lens opacities may be seen in conjunction with lenticonus, occasionally resulting from rupture of the anterior lens capsule.</p>
                <p>All reported individuals with anterior lenticonus who have been adequately examined have exhibited evidence of chronic nephritis and sensorineural hearing loss. It is far more common in affected males but can occur in females. The frequency of lenticonus in males with XLAS was 13% in one large series; its occurrence is related to the pathogenic variant (see <xref ref-type="sec" rid="alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</xref>).</p>
              </list-item>
              <list-item>
                <p><bold>Maculopathy</bold> consisting of whitish or yellowish flecks or granulations in the perimacular region was found in approximately 14% of males with XLAS in a large series. The maculopathy does not appear to be associated with any visual abnormalities.</p>
              </list-item>
              <list-item>
                <p><bold>Corneal endothelial vesicles</bold> (posterior polymorphous dystrophy) and <bold>recurrent corneal erosion</bold> may also be seen in individuals with Alport syndrome.</p>
              </list-item>
            </list>
            <p><bold>Aneurysms of the thoracic and abdominal aorta</bold> have been described in a small number of males with Alport syndrome [<xref ref-type="bibr" rid="alport.REF.lyons.2007.816">Lyons et al 2007</xref>, <xref ref-type="bibr" rid="alport.REF.kashtan.2010.3554">Kashtan et al 2010</xref>].</p>
          </sec>
          <sec id="alport.TBMN">
            <title>TBMN</title>
            <p>Like Alport syndrome, TBMN is characterized clinically by persistent microscopic hematuria often first observed in childhood. In some individuals, microhematuria is intermittent and may not be detected until adulthood. Episodic gross hematuria, frequently in association with upper respiratory infections, is not unusual. The hematuria of TBMN appears to be lifelong.</p>
            <p>TBMN differs clinically from Alport syndrome in the following important respects:</p>
            <list list-type="bullet">
              <list-item>
                <p>It is only rarely associated with extrarenal abnormalities.</p>
              </list-item>
              <list-item>
                <p>Proteinuria and hypertension and progression to ESRD are unusual.</p>
              </list-item>
              <list-item>
                <p>Gender differences in expression of TBMN are not apparent.</p>
              </list-item>
            </list>
            <p>Although overt proteinuria and hypertension are unusual in TBMN, they have been described [<xref ref-type="bibr" rid="alport.REF.van_paassen.2004.909">van Paassen et al 2004</xref>]. Some of these cases may represent individuals who actually have Alport syndrome, and in whom the predominant abnormality of GBM is attenuation, rather than thickening and multilamellation.</p>
            <p>Other glomerular disorders including IgA nephropathy and focal segmental glomerulosclerosis may co-occur in individuals with TBMN [<xref ref-type="bibr" rid="alport.REF.norby.2005.176">Norby &#x00026; Cosio 2005</xref>].</p>
          </sec>
        </sec>
        <sec id="alport.GenotypePhenotype_Correlations__X">
          <title>Genotype-Phenotype Correlations &#x02013; XLAS</title>
          <p>
            <bold>Risk for renal disease</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Large rearrangements and pathogenic nonsense and frameshift variants confer a 90% probability of end-stage renal disease (ESRD) before age 30 years, with 50% reaching ESRD by age 20 years [<xref ref-type="bibr" rid="alport.REF.jais.2000.649">Jais et al 2000</xref>].</p>
            </list-item>
            <list-item>
              <p>In affected individuals with splice-site variants, the probability of ESRD before age 30 years is 70%, with 50% reaching ESRD by age 25 years.</p>
            </list-item>
            <list-item>
              <p>Missense variants are associated with only a 50% probability of ESRD before age 30 years and a renal half-life (the time it takes for 50% of the group to reach end stage, i.e., the need for dialysis or transplantation) of 32 years.</p>
            </list-item>
            <list-item>
              <p>In one study, <italic toggle="yes">COL4A5</italic> missense variants that alter glycine and non-glycine residues in the 3' portion of were associated with earlier development of ESRD, compared with missense variants that alter glycine residues in the 5' portion of the gene [<xref ref-type="bibr" rid="alport.REF.gross.2002.1218">Gross et al 2002</xref>]. In another study, pathogenic variants at the 5' end of <italic toggle="yes">COL4A5</italic> were associated with earlier ESRD, hearing loss, and ocular changes [<xref ref-type="bibr" rid="alport.REF.bekheirnia.2010.876">Bekheirnia et al 2010</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Risk for deafness</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In individuals with large rearrangements of <italic toggle="yes">COL4A5</italic> or nonsense, frameshift, or splice site variants, the risk for deafness is 50% at age ten years.</p>
            </list-item>
            <list-item>
              <p>In individuals with missense variants, the risk for deafness does not reach 50% until age 20 years.</p>
            </list-item>
          </list>
          <p><bold>Risk for anterior lenticonus.</bold> Anterior lenticonus occurs in approximately 15% of males with XLAS. Anterior lenticonus is almost entirely restricted to families with Alport syndrome with hearing loss and progression to ESRD before age 30 years. This observation is explained by the finding that lenticonus is significantly more common in individuals with a <italic toggle="yes">COL4A5</italic> deletion or a small pathogenic variant resulting in a premature stop codon than in those with pathogenic missense or splice-site variants [<xref ref-type="bibr" rid="alport.REF.jais.2000.649">Jais et al 2000</xref>].</p>
          <p>
            <bold>Risk for diffuse leiomyomatosis</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>All families in which XLAS cosegregates with diffuse leiomyomatosis exhibit large deletions that span the adjacent 5' ends of <italic toggle="yes">COL4A5</italic> and <italic toggle="yes">COL4A6</italic>. These deletions involve varying lengths of <italic toggle="yes">COL4A5</italic>, but the <italic toggle="yes">COL4A6</italic> breakpoint is always located in the second intron of the gene [<xref ref-type="bibr" rid="alport.REF.antignac.1996.172">Antignac &#x00026; Heidet 1996</xref>].</p>
            </list-item>
            <list-item>
              <p>Leiomyomatosis does not occur in individuals with deletions of <italic toggle="yes">COL4A5</italic> and <italic toggle="yes">COL4A6</italic> that extend beyond intron 2 of <italic toggle="yes">COL4A6</italic>.</p>
            </list-item>
            <list-item>
              <p>Pathogenic variants of <italic toggle="yes">COL4A6</italic> alone do not appear to cause Alport syndrome, a finding consistent with the absence of the &#x003b1;6(IV) chain from normal GBM.</p>
            </list-item>
          </list>
        </sec>
        <sec id="alport.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance may be decreased in ADAS; at present, data are insufficient to draw a definitive conclusion.</p>
        </sec>
        <sec id="alport.Nomenclature">
          <title>Nomenclature</title>
          <p>The term &#x0201c;benign familial hematuria&#x0201d; is no longer used; it has been replaced with &#x0201c;thin basement membrane nephropathy.&#x0201d;</p>
        </sec>
        <sec id="alport.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of Alport syndrome has been estimated at 1:50,000 live births [<xref ref-type="bibr" rid="alport.REF.levy.2000.925">Levy &#x00026; Feingold 2000</xref>]. Data from several series suggest that approximately one fifth of children evaluated by pediatric nephrologists for isolated microhematuria receive a diagnosis of Alport syndrome. According to the United States Renal Data System (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.usrds.org/">USRDS</ext-link>), approximately 0.2% of adults and 3% of children in the United States with ESRD carry a diagnosis of Alport syndrome.</p>
          <p>TBMN of all causes is estimated to affect 1% of the population; the proportion caused by pathogenic variants in <italic toggle="yes">COL4A3</italic> and <italic toggle="yes">COL4A4</italic> is unknown.</p>
        </sec>
      </sec>
      <sec id="alport.Genetically_Related_Allelic_Disor">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold>Alport syndrome with diffuse leiomyomatosis</bold> results from large deletions that span the adjacent 5' ends of <italic toggle="yes">COL4A5</italic> and <italic toggle="yes">COL4A6</italic> [<xref ref-type="bibr" rid="alport.REF.zhou.1993.1167">Zhou et al 1993</xref>] (see <xref ref-type="sec" rid="alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</xref>). The association of Alport syndrome with diffuse leiomyomatosis of the esophagus and tracheobronchial tree has been reported in several dozen families [<xref ref-type="bibr" rid="alport.REF.antignac.1996.172">Antignac &#x00026; Heidet 1996</xref>, <xref ref-type="bibr" rid="alport.REF.mothes.2002.70">Mothes et al 2002</xref>]. Symptoms usually appear in late childhood and include dysphagia, postprandial vomiting, retrosternal or epigastric pain, recurrent bronchitis, dyspnea, cough, and stridor. Affected females in these kindreds typically exhibit genital leiomyomas as well, causing clitoral hypertrophy with variable involvement of the labia majora and uterus. Bilateral posterior subcapsular cataracts also occur frequently in affected individuals.</p>
        <p><bold>AMME complex</bold> (<italic toggle="yes">A</italic>lport syndrome, intellectual disability [<italic toggle="yes">m</italic>ental retardation], <italic toggle="yes">m</italic>idface hypoplasia, and <italic toggle="yes">e</italic>lliptocytosis) was described in two brothers shown to have a microdeletion of Xq22.3 involving all of <italic toggle="yes">COL4A5</italic> and extending beyond its 3' end [<xref ref-type="bibr" rid="alport.REF.jonsson.1998.273">Jonsson et al 1998</xref>, <xref ref-type="bibr" rid="alport.REF.meloni.2002.359">Meloni et al 2002</xref>].</p>
      </sec>
      <sec id="alport.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <sec id="alport.Conditions_with_Hematuria">
          <title>Conditions with Hematuria</title>
          <p>Alport syndrome most often presents in childhood, and thus must be differentiated from other causes of persistent (&#x0003e;6 months in duration) microhematuria in children.</p>
          <list list-type="bullet">
            <list-item>
              <p>The first step in the evaluation of hematuria in children is to attempt to establish the source of the hematuria (renal/glomerular, renal/post-glomerular, post-renal).</p>
              <list list-type="bullet">
                <list-item>
                  <p>This often involves evaluation of urinary erythrocyte morphology by phase contrast microscopy, urinary calcium measurement, and/or renal ultrasound examination.</p>
                </list-item>
                <list-item>
                  <p>Family history is an important component of the initial evaluation of the child with hematuria. When possible, obtaining urinalyses on first-degree relatives can also be informative.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Once microhematuria is provisionally localized to the glomeruli, possible etiologies include a number of chronic glomerulopathies.</p>
              <list list-type="bullet">
                <list-item>
                  <p>In the child with no known family history of hematuria, the most likely diagnoses are IgA nephropathy, thin basement membrane nephropathy (TBMN), Alport syndrome, and membranoproliferative glomerulonephritis (see <related-object link-type="booklink" source-id="gene" document-id="mpgn" document-type="chapter">Dense Deposit Disease/Membranoproliferative Glomerulonephritis Type II</related-object>).</p>
                </list-item>
                <list-item>
                  <p>In the child with familial hematuria, the diagnostic possibilities narrow down to TBMN and Alport syndrome, although IgA nephropathy is occasionally familial.</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="alport.Combined_Nephritis_and_Deafness">
          <title>Combined Nephritis and Deafness</title>
          <p><bold>Fechtner/Epstein syndrome.</bold> The eponym Fechtner syndrome refers to the association of hereditary nephritis, sensorineural deafness, cataracts, and the triad of the May-Hegglin anomaly (thrombocytopenia, large platelets, and characteristic leukocyte inclusions ["D&#x000f6;hle-like" bodies]). It is transmitted in an autosomal dominant manner. Epstein syndrome (the combination of nephritis, deafness, thrombocytopenia, and large platelets) and Fechtner syndrome were previously considered possible genetic variants of Alport syndrome. Some individuals with these disorders exhibit ultrastructural changes of the glomerular capillary wall reminiscent of those seen in individuals with Alport syndrome. However, these syndromes have been determined to be genetically distinct from Alport syndrome as both result from pathogenic variants in <italic toggle="yes">MYH9</italic>, the gene encoding myosin-9 [<xref ref-type="bibr" rid="alport.REF.seri.2000.103">Seri et al 2000</xref>, <xref ref-type="bibr" rid="alport.REF.ghiggeri.2003.95">Ghiggeri et al 2003</xref>, <xref ref-type="bibr" rid="alport.REF.kunishima.2003.115">Kunishima et al 2003</xref>]. (See <related-object link-type="booklink" source-id="gene" document-id="myh9" document-type="chapter"><italic toggle="yes">MYH9</italic>-Related Disorders</related-object><italic toggle="yes">.</italic>)</p>
        </sec>
      </sec>
      <sec id="alport.Management">
        <title>Management</title>
        <sec id="alport.Evaluations_Following_Initial_Dia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Alport syndrome and thin basement membrane nephropathy (TBMN) the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Evaluation of renal function</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Overt proteinuria (urine protein-creatinine ratio &#x0003e;0.2 or, in a child, 24-hour urine protein &#x0003e;4 mg/m<sup>2</sup>/hr) is an important indicator of renal disease progression in individuals with Alport syndrome and thin basement membrane nephropathy. Urine protein excretion should be assessed at the time of diagnosis and at least annually thereafter.</p>
                </list-item>
                <list-item>
                  <p>In Alport syndrome and thin basement membrane nephropathy, decreased glomerular filtration and hypertension rarely appear before overt proteinuria. Once overt proteinuria has developed, renal function should be assessed periodically by serum creatinine concentration or other estimates of glomerular filtration rate (e.g., creatinine clearance or serum cystatin C levels) and blood pressure should be monitored.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Hearing evaluation.</bold> High-frequency sensorineural deafness typically becomes detectable by audiogram in late childhood (age 6-10 years) in boys with XLAS and in boys and girls with ARAS.</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation</p>
              <list list-type="bullet">
                <list-item>
                  <p>Assessment of ocular status is often unnecessary if the diagnosis of Alport syndrome is established by other means. The maculopathy is asymptomatic, and anterior lenticonus is also frequently asymptomatic.</p>
                </list-item>
                <list-item>
                  <p>Individuals who experience acute corneal erosion should be seen by an ophthalmologist.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Cardiac evaluation.</bold> Baseline evaluation including echocardiogram for aortic dilation in males with XLAS is indicated.</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="alport.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Clinical practice recommendations for the treatment of individuals with Alport syndrome have been published [<xref ref-type="bibr" rid="alport.REF.kashtan.2013.5">Kashtan et al 2013</xref>]. These recommendations encourage early detection of microalbuminuria and proteinuria through regular surveillance and early intervention aimed at suppressing proteinuria using angiotensin antagonists (click <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505543/">here</ext-link> for full text).</p>
          <p><bold>Renal.</bold> Hypertensive individuals should receive appropriate management.</p>
          <p>Controlled clinical trials of therapy for Alport nephropathy have not been conducted. However, a retrospective analysis of a registry population suggested that early treatment with angiotensin blockade delays the onset of ESRD in human Alport syndrome [<xref ref-type="bibr" rid="alport.REF.gross.2012.494">Gross et al 2012</xref>]. The angiotensin receptor blocker losartan has been shown to reduce proteinuria in children with Alport syndrome [<xref ref-type="bibr" rid="alport.REF.webb.2013.737">Webb et al 2013</xref>]. Furthermore, angiotensin blockade has been shown to delay progression to ESRD in transgenic mice with ARAS [<xref ref-type="bibr" rid="alport.REF.gross.2003.1122">Gross et al 2003</xref>, <xref ref-type="bibr" rid="alport.REF.gross.2004.1716">Gross et al 2004</xref>]. Therefore, affected individuals are frequently treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers once proteinuria appears. This form of therapy is rarely associated with significant adverse effects. It is unknown whether the losartan therapy reduces the risk for aortic dilation in XLAS (as is being investigated for <related-object link-type="booklink" source-id="gene" document-id="marfan" document-type="chapter">Marfan syndrome</related-object>).</p>
          <p><bold>Renal transplantation</bold> is typically successful in individuals with Alport syndrome [<xref ref-type="bibr" rid="alport.REF.kashtan.1995.679">Kashtan et al 1995</xref>, <xref ref-type="bibr" rid="alport.REF.byrne.2002.769">Byrne et al 2002</xref>]. Anti-GBM nephritis involving the renal allograft is a dramatic, but rare, complication occurring in an estimated 3% of males with Alport syndrome who have undergone transplantation [<xref ref-type="bibr" rid="alport.REF.kashtan.1999.338">Kashtan 1999</xref>, <xref ref-type="bibr" rid="alport.REF.byrne.2002.769">Byrne et al 2002</xref>].</p>
          <p>Prior to renal transplantation, males with XLAS should have a cardiac evaluation for aortic dilation [<xref ref-type="bibr" rid="alport.REF.kashtan.2010.3554">Kashtan et al 2010</xref>].</p>
          <p>Special considerations apply to the selection of potential living related kidney donors for individuals with XLAS. The following discussion considers potential donors on the basis of gender and the presence or absence of hematuria:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Male relative without hematuria.</bold> The optimal living related donor is a male who has a normal urinalysis and is therefore unaffected.</p>
            </list-item>
            <list-item>
              <p><bold>Male relative with hematuria.</bold> A related male with hematuria probably has Alport syndrome, and cannot be a kidney donor.</p>
            </list-item>
            <list-item>
              <p><bold>Female relative without hematuria.</bold> Female relatives who have normal urinalyses are probably unaffected, although approximately 5%-10% of females heterozygous for a <italic toggle="yes">COL4A5</italic> pathogenic variant are asymptomatic. It is rare for asymptomatic females whose children are also asymptomatic to be heterozygous. Asymptomatic females can probably donate a kidney safely, but should be informed of their risk of having affected male children to whom they will not be able to donate a kidney. Genetic status can be confirmed or excluded by molecular genetic testing if the pathogenic variant in the family is known.</p>
            </list-item>
            <list-item>
              <p><bold>Female relative with hematuria (i.e., heterozygous female).</bold> Females heterozygous for a <italic toggle="yes">COL4A5</italic> pathogenic variant should only be considered as potential kidney donors if no asymptomatic living donors are available.</p>
              <list list-type="bullet">
                <list-item>
                  <p>The presence of proteinuria or sensorineural deafness is an absolute contraindication to kidney donation as these are risk factors for progression to ESRD.</p>
                </list-item>
                <list-item>
                  <p>Heterozygous females younger than age 40 years should not be used as donors, even in the absence of proteinuria or deafness.</p>
                </list-item>
                <list-item>
                  <p>Heterozygous females age 40 years or older who have normal renal function, blood pressure, and hearing and no proteinuria can be considered as donors because the risk of late progression to ESRD appears to be low in such individuals. However, the donor should be informed of the risk (albeit low) of late progression to ESRD.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Cochlear.</bold> Hearing aids should be prescribed when appropriate.</p>
          <p><bold>Ocular.</bold> The ocular manifestations of Alport syndrome rarely require specific ophthalmologic intervention.</p>
          <p>Some individuals develop cataracts that interfere with vision; these should be extracted when necessary.</p>
          <p><bold>Diffuse leiomyomatosis.</bold> Symptomatic leiomyomas may require surgical intervention.</p>
        </sec>
        <sec id="alport.Prevention_of_Secondary_Complicat">
          <title>Prevention of Secondary Complications</title>
          <p>Individuals who suffer recurrent corneal erosions may need to take measures (e.g., wearing goggles when riding a bicycle) to protect their corneas from minor trauma.</p>
          <p>Exposure to loud noise should be minimized.</p>
        </sec>
        <sec id="alport.Surveillance">
          <title>Surveillance</title>
          <p>Clinical practice recommendations for the treatment and health surveillance of individuals with Alport syndrome have been published [<xref ref-type="bibr" rid="alport.REF.kashtan.2013.5">Kashtan et al 2013</xref>].</p>
          <p>Individuals with a diagnosis of Alport syndrome or thin basement membrane nephropathy should be followed by a nephrologist in addition to a primary care physician. Once overt proteinuria has developed, renal function should be assessed periodically by serum creatinine concentration or other estimates of glomerular filtration rate (e.g., creatinine clearance or serum cystatin C levels), and blood pressure should be monitored.</p>
          <p>Although most females with XLAS exhibit only asymptomatic microhematuria, recent data indicate a significant risk for progression to ESRD [<xref ref-type="bibr" rid="alport.REF.jais.2003.2603">Jais et al 2003</xref>]. For this reason, all women with a diagnosis of Alport syndrome need to be monitored regularly for the development of proteinuria and hypertension.</p>
          <p>Children with Alport syndrome should have audiologic evaluation every one to two years beginning at age six to seven years (see <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Hereditary Hearing Loss and Deafness Overview</related-object>).</p>
          <p>Periodic cardiac evaluation for aortic dilation for males with XLAS is appropriate.</p>
          <p>Transplant recipients should be monitored for development of anti-glomerular basement membrane antibody-mediated glomerulonephritis.</p>
        </sec>
        <sec id="alport.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate family members at risk for Alport syndrome or thin basement membrane nephropathy in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Urinalysis</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>Males.</bold> A single urinalysis is sufficient in a male.</p>
                </list-item>
                <list-item>
                  <p><bold>Females.</bold> Several urinalyses should be performed in females before concluding that hematuria is absent.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Molecular genetic testing.</bold> If the pathogenic variant(s) in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk family members. Molecular genetic testing is necessary to exclude heterozygosity in an at-risk female who does not have hematuria.</p>
            </list-item>
          </list>
          <p>Relatives found to have proteinuria, hypertension, and/or a pathogenic variant should be referred to a nephrologist for further evaluation. In the absence of proteinuria or hypertension, relatives at risk should, at a minimum, have an annual urinalysis and measurement of blood pressure if molecular genetic testing is not available.</p>
          <p>See <xref ref-type="sec" rid="alport.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="alport.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="alport.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="alport.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Alport syndrome caused by mutation of <italic toggle="yes">COL4A5</italic> is inherited in an X-linked manner (XLAS).</p>
          <p>Alport syndrome caused by mutation of <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> can be inherited in an autosomal recessive (ARAS) or autosomal dominant manner (ADAS).</p>
          <p>Thin basement membrane nephropathy (TBMN) caused by mutation of <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> has only been described as being inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="alport.Risk_to_Family_Members__XLinked_I">
          <title>Risk to Family Members &#x02013; X-Linked Inheritance</title>
          <p>
            <bold>Parents of a male proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of a male with XLAS will not have the disease nor will he be hemizygous for the <italic toggle="yes">COL4A5</italic> pathogenic variant; therefore, he does not require further evaluation/testing.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected male, the mother of an affected individual is an obligate heterozygote.</p>
            </list-item>
            <list-item>
              <p>If only one male in a family is affected, the likelihood that that individual's mother is heterozygous is 85%-90%. Approximately 10%-15% of male probands have XLAS as the result of a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The mother of a male known to have XLAS should have a urinalysis and/or molecular genetic testing if the pathogenic variant has been identified in the proband.</p>
              <list list-type="bullet">
                <list-item>
                  <p>The presence of microhematuria indicates that she is likely to be heterozygous for a <italic toggle="yes">COL4A5</italic> pathogenic variant.</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>If proteinuria or hypertension is present, she should be referred to a nephrologist for further evaluation.</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>Molecular genetic testing is necessary to exclude the carrier state in an at-risk female who does not have hematuria.</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>In the absence of proteinuria or hypertension, she should, at a minimum, have an annual urinalysis and measurement of blood pressure if molecular genetic testing has not excluded the carrier state.</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Parents of a female proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father or the mother of a female proband may have the <italic toggle="yes">COL4A5</italic> pathogenic variant, or the proband may have a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Approximately 10%-15% of affected individuals have XLAS as the result of a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Evaluation of parents of a female proband with XLAS begins with urinalysis and proceeds as described for the mother of a male proband.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a male proband.</bold> The risk to the sibs of a male proband depends on the genetic status of the mother:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the mother is heterozygous, each sib has a 50% chance of inheriting the <italic toggle="yes">COL4A5</italic> pathogenic variant:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Males who inherit the pathogenic variant will be affected.</p>
                </list-item>
                <list-item>
                  <p>Females who inherit the pathogenic variant may or may not be symptomatic.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>If the mother is not heterozygous, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a female proband.</bold> The risk to the sibs of a female proband depends on the genetic status of the parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the mother is heterozygous, each sib has a 50% chance of inheriting the <italic toggle="yes">COL4A5</italic> pathogenic variant:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Males who inherit the pathogenic variant will be affected.</p>
                </list-item>
                <list-item>
                  <p>Females who inherit the pathogenic variant may or may not be symptomatic.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>If the father has a pathogenic variant, all of his daughters will inherit the pathogenic variant and may or may not have symptoms. None of his sons will inherit the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>If neither parent has a pathogenic variant, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a male proband.</bold> Affected males transmit the <italic toggle="yes">COL4A5</italic> pathogenic variant to all of their daughters and to none of their sons.</p>
          <p><bold>Offspring of a female proband.</bold> Women with a <italic toggle="yes">COL4A5</italic> pathogenic variant have a 50% chance of transmitting the pathogenic variant to each child:</p>
          <list list-type="bullet">
            <list-item>
              <p>Sons who inherit the pathogenic variant will be affected.</p>
            </list-item>
            <list-item>
              <p>Daughters will have a range of possible phenotypic expression.</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> The male proband's maternal aunts may be at risk of being heterozygous and the aunts' offspring, depending on their gender, may be at risk of being heterozygous for the pathogenic variant or being affected.</p>
        </sec>
        <sec id="alport.Heterozygote_Carrier_Detection__X">
          <title>Heterozygote (Carrier) Detection &#x02013; X-Linked Inheritance</title>
          <p>Molecular genetic testing for at-risk females who lack microhematuria requires prior identification of the pathogenic variant in the family.</p>
          <p>Note: (1) Females are heterozygotes for this X-linked disorder and may develop clinical findings related to the disorder. (2) Identification of female heterozygotes requires either (a) prior identification of the pathogenic variant in the family or, (b) if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and then, if a pathogenic variant is not identified, by methods to detect gross structural abnormalities.</p>
        </sec>
        <sec id="alport.Risk_to_Family_Members__Autosomal">
          <title>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Approximately 50% of heterozygotes (carriers) exhibit persistent or intermittent microhematuria. Carriers of ARAS rarely develop proteinuria, hypertension, or renal insufficiency.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Approximately 50% of carriers exhibit persistent or intermittent microhematuria. Carriers of ARAS rarely develop proteinuria, hypertension, or renal insufficiency.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with ARAS are obligate heterozygotes (carriers) for a <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of a <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> pathogenic variant.</p>
        </sec>
        <sec id="alport.Carrier_Heterozygote_Detection__A">
          <title>Carrier (Heterozygote) Detection &#x02013; Autosomal Recessive Inheritance</title>
          <p>Carrier testing of at-risk relatives is possible if the <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> pathogenic variants have been identified in the family.</p>
        </sec>
        <sec id="alport.Risk_to_Family_Members__Autosomal_1">
          <title>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with ADAS or TBMN have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with an ADAS or TBMN may have the disorder as the result of a <italic toggle="yes">de novo</italic>
<italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown.</p>
            </list-item>
            <list-item>
              <p>Urinalysis is recommended for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant and/or molecular genetic testing if the pathogenic variant has been identified in the proband.</p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with ADAS or TBMN have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of a proband depends on the genetic the status of the parents.</p>
              <list list-type="bullet">
                <list-item>
                  <p>If a parent of the proband is affected, the risk is 50%.</p>
                </list-item>
                <list-item>
                  <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>No instances of germline mosaicism have been reported, although it remains a possibility.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Offspring of an individual with ADAS or TBMN are at a 50% risk of inheriting the <italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected, his or her family members are at risk.</p>
        </sec>
        <sec id="alport.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="alport.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Screening of potential living related kidney donors.</bold> Most individuals with Alport syndrome who require kidney transplantation have X-linked disease. Both hemizygous males and heterozygous females with XLAS are at risk for ESRD. Potential living related donors must be evaluated carefully to avoid nephrectomy in an affected individual. <xref ref-type="bibr" rid="alport.REF.kashtan.2006.651">Kashtan [2006]</xref> discusses in detail the evaluation of potential donors.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p><bold>X-linked</bold> or <bold>autosomal recessive inheritance.</bold> It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are heterozygous, or are at risk of being heterozygous.</p>
            </list-item>
            <list-item>
              <p><bold>Autosomal dominant inheritance.</bold> It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="alport.Prenatal_Testing_and_Preimplantat">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">COL4A3</italic>, <italic toggle="yes">COL4A4</italic>, or <italic toggle="yes">COL4A5</italic> pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk for Alport syndrome and thin basement membrane nephropathy and preimplantation genetic diagnosis are possible options.</p>
          <p>Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="alport.Resources">
        <title>Resources</title>
      </sec>
      <sec id="alport.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="alport.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Basement membranes, the sheet-like structures that support epithelial and endothelial cells, display heterogeneity in protein composition, ultrastructural features, and function. Basement membranes are composed of several major and minor glycoprotein constituents. Type IV collagen is present ubiquitously in basement membranes, where it is the major collagenous component. Type IV collagen molecules secreted by endothelial and epithelial cells self-associate into polygonal networks, which interact with laminin networks, as well as with nidogen, proteoglycans, and other glycoproteins, to form basement membranes.</p>
          <p>It is now clear that the tissue pathology and clinical features of Alport syndrome result from abnormalities of basement membrane expression of the collagen &#x003b1;3, &#x003b1;4, &#x003b1;5, and possibly &#x003b1;6(IV) chains. These chains are usually absent from or under-expressed in the basement membranes of individuals with Alport syndrome, such that the networks that they form are absent or, if present, defective in structure and function.</p>
          <p>In the normal developing kidney, collagen &#x003b1;1(IV) and collagen &#x003b1;2(IV) chains predominate in the primordial glomerular basement membrane (GBM) of immature glomeruli. The formation of capillary loops within the maturing glomeruli is associated with the appearance of collagen &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains in the GBM. As glomerular maturation progresses, the &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains become the predominant type IV collagen chains in GBM. This process has been referred to as "isotype switching." Although an isotype switch does not occur in most males with Alport syndrome, glomerular development otherwise proceeds normally and the GBM of young animals and children with Alport syndrome exhibits a normal trilaminar appearance by electron microscopy. These glomeruli exhibit normal capacities for filtration and for selective permeability, as demonstrated by the normal glomerular filtration rates and absence of overt proteinuria that are characteristic of early Alport syndrome in both humans and animals. Therefore, it appears that proteinuria and renal insufficiency, as well as sensorineural deafness, come about as the result of processes initiated by the absence of the collagen &#x003b1;3-&#x003b1;4-&#x003b1;5(IV) network, rather than arising directly from the absence of this network.</p>
          <p>The most straightforward demonstration of the consequences arising directly from the absence of the collagen &#x003b1;3-&#x003b1;4-&#x003b1;5(IV) network from basement membranes may be anterior lenticonus, in which the anterior lens capsule lacks the strength to maintain the normal conformation of the lens. Microhematuria, the first and invariable renal manifestation of Alport syndrome, probably reflects GBM thinning and a tendency to develop focal ruptures caused by the absent or defective expression of the collagen &#x003b1;3-&#x003b1;4- &#x003b1;5(IV) network. Episodic gross hematuria precipitated by infections, which is not uncommon during the first two decades of life, may reflect increased susceptibility of the Alport GBM to proteolysis.</p>
          <p>The processes that bring about GBM thickening, proteinuria, and renal insufficiency in males with XLAS and in both males and females with ARAS remain undefined, although there are some clues to what may be occurring. Unlike other glomerulopathies, Alport syndrome is characterized by the accumulation of the collagen &#x003b1;1(IV) and &#x003b1;2(IV) chains, along with types V and VI collagen, in the GBM. These proteins appear to spread from their normal subendothelial location, occupying the full width of the GBM. As Alport glomeruli undergo sclerosis, the collagen &#x003b1;1(IV) and &#x003b1;2(IV) chains disappear from the GBM, but type V and type VI collagen persist and, in fact, continue to accumulate. It is possible that the altered expression of the collagen &#x003b1;1(IV) and &#x003b1;2(IV) chains, type V collagen and type VI collagen represents a compensatory response to the loss of the collagen &#x003b1;3(IV), &#x003b1;4(IV), and &#x003b1;5(IV) chains from GBM, or it may simply reflect altered gene expression resulting from changes in signaling from the extracellular matrix to the nucleus. In transgenic mice with ARAS caused by partial deletion of COL4A3, renal mRNA levels for the collagen &#x003b1;1(IV) and &#x003b1;2(IV) chains progressively increase, suggesting activation of these genes. Whatever the underlying mechanism, the unrestrained deposition of certain collagens in GBM may contribute to glomerulosclerosis in Alport syndrome.</p>
          <sec id="alport.COL4A3">
            <title>
              <italic toggle="yes">COL4A3</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">COL4A3</italic> contains 52 exons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000091.3">NM_000091.3</ext-link>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="alport" object-id="alport.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Benign variants.</bold> Several benign variants in <italic toggle="yes">COL4A3</italic> have been described.</p>
            <p><bold>Pathogenic variants.</bold> Relatively few <italic toggle="yes">COL4A3</italic> pathogenic variants have been reported. However, pathogenic variants in this gene appear to exhibit the same variety as seen in <italic toggle="yes">COL4A5</italic>, with a predilection for glycine substitutions in the collagenous domains of the collagen &#x003b1;3(IV) chain.</p>
            <p><bold>Normal gene product.</bold> The gene products of <italic toggle="yes">COL4A3</italic>, <italic toggle="yes">COL4A4</italic>, and <italic toggle="yes">COL4A5</italic> are, respectively, the &#x003b1;3, &#x003b1;4, and &#x003b1;5 chains of type IV collagen [&#x003b1;3(IV), &#x003b1;4(IV), and &#x003b1;5(IV)]. The six type IV collagen &#x003b1; chains share basic structural features and show extensive sequence homology. The major structural features of &#x003b1;(IV) chains are: a collagenous domain of approximately 1400 residues containing the repetitive triplet sequence glycine (Gly)-X-Y, in which X and Y represent a variety of other amino acids; a carboxy-terminal non-collagenous (NC1) domain of approximately 230 residues; and a non-collagenous aminoterminal sequence of 15-20 residues. Approximately 20 interruptions of the collagenous triplet sequence are present in the collagenous domain. The NC1 domains each contain 12 completely conserved cysteine residues, which participate in intrachain and interchain disulfide bonds.</p>
            <p>Type IV collagen chains form heterotrimers through associations between their COO- NC1 domains, associated with folding of the collagenous domains into triple helices.</p>
            <p>Type IV collagen heterotrimers form networks through several types of intermolecular interaction. These include end-to-end linkages between the COO- NC1 domains of two heterotrimers, covalent interactions between four heterotrimers at their NH- ends, and lateral associations between heterotrimers via binding of the COO- domains to sites along the collagenous region of another heterotrimer. Disulfide bonds involving conserved cysteine residues are critical to the interactions between NC1 domains. These various linkages between type IV collagen molecules produce a nonfibrillar polygonal assembly that serves as scaffolding for the deposition of other matrix glycoproteins and for cell attachment.</p>
            <p><bold>Abnormal gene product.</bold> The abnormalities of type IV collagen expression observed in individuals with XLAS and ARAS indicate that a pathogenic variant affecting one of the chains involved in the putative collagen 3- 4- 5(IV) network can prevent basement membrane expression not only of that chain but of the other two chains as well. Similarly, a pathogenic variant involving the collagen 5(IV) chain can interfere with basement membrane expression of collagen 6(IV). The mechanisms that produce these effects remain under investigation. It is likely that at least some pathogenic variants interfere in various ways with the formation of trimeric type IV collagen molecules, leading to degradation of normal chains that have been prevented from forming trimers or that have formed abnormal trimers. This kind of process accounts for abnormal type I collagen deposition in bone in <related-object link-type="booklink" source-id="gene" document-id="oi" document-type="chapter">osteogenesis imperfecta</related-object>. Most of the available data suggest that <italic toggle="yes">COL4A5</italic> pathogenic variants do not suppress transcription of <italic toggle="yes">COL4A3</italic>, <italic toggle="yes">COL4A4</italic>, and <italic toggle="yes">COL4A6</italic>.</p>
          </sec>
          <sec id="alport.COL4A4">
            <title>
              <italic toggle="yes">COL4A4</italic>
            </title>
            <p><bold>Gene structure</bold>
<italic toggle="yes">COL4A4</italic> includes 48 exons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000092.4">NM_000092.4</ext-link>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="alport" object-id="alport.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Benign variants.</bold> Several benign variants in <italic toggle="yes">COL4A4</italic> have been described.</p>
            <p><bold>Pathogenic variants.</bold> Relatively few <italic toggle="yes">COL4A4</italic> pathogenic variants have been reported. However, pathogenic variants in this gene appear to exhibit the same variety as <italic toggle="yes">COL4A5</italic>, with a predilection for glycine substitutions in the collagenous domains of the collagen &#x003b1;4(IV) chain.</p>
            <p><bold>Normal gene product.</bold> See <xref ref-type="sec" rid="alport.COL4A3"><italic toggle="yes">COL4A3</italic></xref>.</p>
            <p><bold>Abnormal gene product.</bold> See <xref ref-type="sec" rid="alport.COL4A3"><italic toggle="yes">COL4A3</italic></xref>.</p>
          </sec>
          <sec id="alport.COL4A5">
            <title>
              <italic toggle="yes">COL4A5</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">COL4A5</italic> consists of 51 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="alport" object-id="alport.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Benign variants.</bold> A variety of benign variants in <italic toggle="yes">COL4A5</italic> have been described.</p>
            <p><bold>Pathogenic variants.</bold> Of the several hundred reported <italic toggle="yes">COL4A5</italic> pathgoenic variants, an estimated 20% are large rearrangements, predominantly deletions [<xref ref-type="bibr" rid="alport.REF.jais.2000.649">Jais et al 2000</xref>]. Missense variants account for approximately 35%-40%, approximately 15% are splice-site variants, and 25%-30% are nonsense variants or small frameshifting deletions or insertions that result in premature stop codons.</p>
            <p>The great majority of missense <italic toggle="yes">COL4A5</italic> variants are guanine substitutions in the first or second position of glycine codons that result in the replacement of a glycine residue in the collagenous domain of the collagen &#x003b1;5(IV) chain by another amino acid. Such pathogenic variants are thought to interfere with the normal folding of the mutant collagen &#x003b1;5(IV) chain into triple helices with other type IV collagen &#x003b1; chains. Glycine lacks a side chain, making it p.Cys1564Ser (c.4692G&#x0003e;A) the least bulky of amino acids and small enough to allow three glycine residues to fit into the interior of a tightly wound triple helix. The presence of a bulkier amino acid in a glycine position presumably creates a kink or an unfolding in the triple helix. Glycine substitutions in the collagen &#x003b1;1(I) chain account for the majority of pathogenic variants causing <related-object link-type="booklink" source-id="gene" document-id="oi" document-type="chapter">osteogenesis imperfecta</related-object> and are common in other genetic disorders of collagen. Abnormally folded collagen triple helices exhibit increased susceptibility to proteolytic degradation. The position of the substituted glycine, or the substituting amino acid itself, may influence the effect of the pathogenic variant on triple helical folding and ultimately the impact of the pathogenic variant on the severity of the clinical phenotype.</p>
            <table-wrap id="alport.T.selected_col4a5_pathogenic_vari" orientation="portrait" position="anchor">
              <label>Table 3. </label>
              <caption>
                <p>Selected <italic toggle="yes">COL4A5</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4692G&#x0003e;C</td>
                    <td headers="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys1564Ser</td>
                    <td headers="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000495.3">NM_000495.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000486.1">NP_000486.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4946T&#x0003e;G</td>
                    <td headers="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu1649Arg</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.5030G&#x0003e;A</td>
                    <td headers="hd_h_alport.T.selected_col4a5_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1677Gln</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> See <xref ref-type="sec" rid="alport.COL4A3"><italic toggle="yes">COL4A3</italic></xref>.</p>
            <p><bold>Abnormal gene product.</bold> Rare missense variants in <italic toggle="yes">COL4A5</italic> involve critical residues in the carboxy-terminal NC1 domain of the collagen &#x003b1;5(IV) chain &#x02014; for example, one of the twelve conserved cysteine moieties. The loss of one of these cysteines would eliminate a disulfide bond, which could interfere with the formation of triple helices, or with the construction of networks involving collagen &#x003b1;5(IV) chains.</p>
          </sec>
        </sec>
      </sec>
      <sec id="alport.References">
        <title>References</title>
        <sec id="alport.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="alport.Literature_Cited.reflist0">
            <ref id="alport.REF.antignac.1996.172">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis.</article-title>
                <source>Contrib Nephrol</source>
                <volume>117</volume>
                <fpage>172</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">8801045</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.arrondel.2004.2030">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arrondel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desch&#x000ea;nes</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Meur</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordonnier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fournier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amadeo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia.</article-title>
                <source>Kidney Int.</source>
                <year>2004</year>
                <volume>65</volume>
                <fpage>2030</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">15149316</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.badenas.2002.1248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Badenas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Praga</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tazon</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arrondel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armengol</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andres</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morales</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camacho</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lens</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davila</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mila</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darnell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torra</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>13</volume>
                <fpage>1248</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11961012</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.bekheirnia.2010.876">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bekheirnia</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reed</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shamshirsaz</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masoumi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrier</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype correlation in X-linked Alport syndrome.</article-title>
                <source>J Am Soc Nephrol</source>
                <year>2010</year>
                <volume>21</volume>
                <fpage>876</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">20378821</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.boye.1998.1329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boye</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mollet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forestier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen-Solal</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunfeld</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palcoux</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <volume>63</volume>
                <fpage>1329</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">9792860</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.buzza.2003.447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buzza</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dagher</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>YY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babon</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cotton</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savige</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Mutations in the COL4A4 gene in thin basement membrane disease.</article-title>
                <source>Kidney Int</source>
                <volume>63</volume>
                <fpage>447</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">12631110</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.byrne.2002.769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budisavljevic</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fan</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Self</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploth</surname>
                    <given-names>DW</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Renal transplant in patients with Alport's syndrome.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>39</volume>
                <fpage>769</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">11920343</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.fallerini.2014.252">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fallerini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dosa</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tita</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Prete</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feriozzi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gai</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clementi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Manna</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miglietti</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandrile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghiggeri</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piaggio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brancati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frate</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinciaroli</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castorina</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giachino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mari</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruttini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ariani</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.</article-title>
                <source>Clin Genet.</source>
                <year>2014</year>
                <volume>86</volume>
                <fpage>252</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24033287</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.ghiggeri.2003.95">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ghiggeri</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caridi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magrini</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sessa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pecci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romagnoli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gangarossa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noris</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sartore</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Necchi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravazzolo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balduini</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome).</article-title>
                <source>Am J Kidney Dis</source>
                <volume>41</volume>
                <fpage>95</fpage>
                <lpage>104</lpage>
                <pub-id pub-id-type="pmid">12500226</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.gross.2012.494">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licht</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anders</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>T&#x000f6;nshoff</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;cker</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wygoda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehrich</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pape</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konrad</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rascher</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000f6;tsch</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Wiefel</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyer</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Study Group Members of the Gesellschaft f&#x000fc;r P&#x000e4;diatrische Nephrologie, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, M&#x000fc;ller GA, Weber M. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.</article-title>
                <source>Kidney Int.</source>
                <year>2012</year>
                <volume>81</volume>
                <fpage>494</fpage>
                <lpage>501</lpage>
                <pub-id pub-id-type="pmid">22166847</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.gross.2002.1218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netzer</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambrecht</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seibold</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>17</volume>
                <fpage>1218</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">12105244</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.gross.2003.1122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netzer</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambrecht</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seibold</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>18</volume>
                <fpage>1122</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12748344</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.gross.2004.1716">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze-Lohoff</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koepke</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beirowski</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Addicks</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bloch</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smyth</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>19</volume>
                <fpage>1716</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">15128880</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.gubler.1995.1142">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beziau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broyer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirson</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddoum</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleppel</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution.</article-title>
                <source>Kidney Int</source>
                <volume>47</volume>
                <fpage>1142</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7783412</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.heidet.2001.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arrondel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forestier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen-Solal</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mollet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stavrou</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Structure of the human type iv collagen gene col4a3 and mutations in autosomal alport syndrome.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>12</volume>
                <fpage>97</fpage>
                <lpage>106</lpage>
                <pub-id pub-id-type="pmid">11134255</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.hertz.2015">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hertz</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomassen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storey</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flinter</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: Alport syndrome - update 2014.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2015</year>
                <volume>23</volume>
                <issue>9</issue>
                <pub-id pub-id-type="pmid">25388007</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.jais.2000.649">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jais</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giatras</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzoni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netzer</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flinter</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirson</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verellen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieslander</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persson</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tryggvason</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hertz</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krejcova</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carvalho</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saus</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>11</volume>
                <fpage>649</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">10752524</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.jais.2003.2603">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jais</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giatras</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzoni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netzer</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flinter</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirson</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieslander</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persson</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tryggvason</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hertz</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carvalho</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saus</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>14</volume>
                <fpage>2603</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">14514738</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.jonsson.1998.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jonsson</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherniske</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruttini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piccini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vitelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballabio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pober</surname>
                    <given-names>BR</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis: a new X linked contiguous gene deletion syndrome?</article-title>
                <source>J Med Genet</source>
                <volume>35</volume>
                <fpage>273</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9598718</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kashtan.1999.338">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes.</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>78</volume>
                <fpage>338</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">10499074</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kashtan.2004.1290">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Diagnosis of Alport syndrome.</article-title>
                <source>Kidney Int</source>
                <volume>66</volume>
                <fpage>1290</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">15327435</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kashtan.2006.651">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Renal transplantation in patients with Alport syndrome.</article-title>
                <source>Pediatr Transplant</source>
                <volume>10</volume>
                <fpage>651</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16911486</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kashtan.2013.5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rheault</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licht</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative.</article-title>
                <source>Pediatr Nephrol.</source>
                <volume>28</volume>
                <fpage>5</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">22461141</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kashtan.1996.142">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleppel</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Immunohistologic findings in Alport syndrome.</article-title>
                <source>Contrib Nephrol</source>
                <volume>117</volume>
                <fpage>142</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">8801043</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kashtan.1995.679">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McEnery</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tejani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stablein</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>9</volume>
                <fpage>679</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">8747103</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kashtan.2010.3554">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segal</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flinter</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makanjuola</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gan</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watnick</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Aortic abnormalities in males with Alport syndrome.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>2010</year>
                <volume>25</volume>
                <fpage>3554</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">20494893</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.king.2006.1061">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flinter</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>A two-tier approach to mutation detection in the COL4A5 gene for Alport syndrome.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>1061</fpage>
                <pub-id pub-id-type="pmid">16941480</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.kunishima.2003.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kunishima</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsushita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kojima</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sako</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jo</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamiya</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations.</article-title>
                <source>Lab Invest</source>
                <volume>83</volume>
                <fpage>115</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">12533692</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.lemmink.1996.1114">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lemmink</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nillesen</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mochizuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunner</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Oost</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnens</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>HJ</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Benign familial hematuria due to mutation of the type IV collagen alpha4 gene.</article-title>
                <source>J Clin Invest</source>
                <volume>98</volume>
                <fpage>1114</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">8787673</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.levy.2000.925">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feingold</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Estimating prevalence in single-gene kidney diseases progressing to renal failure.</article-title>
                <source>Kidney Int</source>
                <volume>58</volume>
                <fpage>925</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">10972657</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.longo.2002.1947">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porcedda</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mari</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giachino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meloni</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deplano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brusco</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massella</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavoratti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roccatello</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frasca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzucco</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muda</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fasciolo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arrondel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome.</article-title>
                <source>Kidney Int</source>
                <volume>61</volume>
                <fpage>1947</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">12028435</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.lyons.2007.816">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lyons</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St. John</surname>
                    <given-names>ERC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morales</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>PR</given-names>
                  </name>
                </person-group>
                <article-title>Ruptured thoracoabdominal aortic aneurysm in a renal transplant patient with Alport's syndrome.</article-title>
                <source>Ann Vasc Surg.</source>
                <year>2007</year>
                <volume>21</volume>
                <fpage>816</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17697765</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.meloni.2002.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meloni</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vitelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pucci</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowry</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonlorenzi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ventura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzoni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pober</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Alport syndrome and mental retardation: clinical and genetic dissection of the contiguous gene deletion syndrome in Xq22.3 (ATS-MR).</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>359</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">12011158</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.mencarelli.2015.163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mencarelli</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storey</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Geel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fallerini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miglietti</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonucci</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cetta</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sayer</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Wijngaard</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yau</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mari</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruttini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ariani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flinter</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Evidence of digenic inheritance in Alport syndrome.</article-title>
                <source>J Med Genet.</source>
                <year>2015</year>
                <volume>52</volume>
                <fpage>163</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">25575550</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.merchant.2004.1609">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Merchant</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgess</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santi</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colvin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nadol</surname>
                    <given-names>JB</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Temporal bone histopathology in alport syndrome.</article-title>
                <source>Laryngoscope</source>
                <volume>114</volume>
                <fpage>1609</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">15475791</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.morini_re.2014.2740">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morini&#x000e8;re</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilbert</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lison</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lebbah</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bole-Feysot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pruvost</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nitschke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plaisier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macher</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noel</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Improving mutation screening in familial hematuric nephropathies through next generation sequencing.</article-title>
                <source>J Am Soc Nephrol.</source>
                <year>2014</year>
                <volume>25</volume>
                <fpage>2740</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">24854265</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.mothes.2002.70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mothes</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arrondel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richter</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiele</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patzer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sado</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheele</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Alport syndrome associated with diffuse leiomyomatosis: COL4A5-COL4A6 deletion associated with a mild form of Alport nephropathy.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>17</volume>
                <fpage>70</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11773466</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.nagel.2005.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nagel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagorka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome.</article-title>
                <source>Hum Mutat</source>
                <volume>26</volume>
                <fpage>60</fpage>
                <pub-id pub-id-type="pmid">15954103</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.norby.2005.176">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Norby</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosio</surname>
                    <given-names>FG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Thin basement membrane nephropathy associated with other glomerular diseases.</article-title>
                <source>Semin Nephrol</source>
                <volume>25</volume>
                <fpage>176</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15880329</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.piccini.1999.464">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Piccini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruttini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volti</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballabio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renieri</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Evidence for genetic heterogeneity in benign familial hematuria.</article-title>
                <source>Am J Nephrol</source>
                <volume>19</volume>
                <fpage>464</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10460935</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.seri.2000.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cusano</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gangarossa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caridi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lo Nigro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghiggeri</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravazzolo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Vecchio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Apolito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iolascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zelante</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balduini</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noris</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magrini</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belletti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heath</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babcock</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glucksman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aliprandis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bizzaro</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martignetti</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.</article-title>
                <source>Nat Genet</source>
                <volume>26</volume>
                <fpage>103</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10973259</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.tiebosch.1989.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiebosch</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frederik</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Breda Vriesman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooy</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Rie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van de Wiel</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolters</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeppenfeldt</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Thin-basement-membrane nephropathy in adults with persistent hematuria.</article-title>
                <source>N Engl J Med</source>
                <volume>320</volume>
                <fpage>14</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">2909874</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.van_der_loop.1999.1217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Loop</surname>
                    <given-names>FT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnens</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemmink</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breuning</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmer</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>HJ</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin.</article-title>
                <source>Kidney Int</source>
                <volume>55</volume>
                <fpage>1217</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">10200983</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.van_paassen.2004.909">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Paassen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Breda Vriesman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Rie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tervaert</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry.</article-title>
                <source>Kidney Int</source>
                <volume>66</volume>
                <fpage>909</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">15327380</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.webb.2013.737">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahinfar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massaad</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gleim</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCrary Sisk</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.</article-title>
                <source>Pediatr Nephrol.</source>
                <year>2013</year>
                <volume>28</volume>
                <fpage>737</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">23207876</pub-id>
              </element-citation>
            </ref>
            <ref id="alport.REF.zhou.1993.1167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mochizuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laurila</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tryggvason</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reeders</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors.</article-title>
                <source>Science</source>
                <volume>261</volume>
                <fpage>1167</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8356449</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="alport.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="alport.Suggested_Reading.reflist0">
            <ref id="alport.REF.ayadi.2008">
              <mixed-citation publication-type="web">Ayadi L, Abbes K, Makni S, Kharrat M, Kallel R, Affes N, Hmida MB, Hachicha J, Beyrouti MI, Boudawara TS. Alport syndrome and diffuse leiomyomatosis. <italic toggle="yes">Atlas of Genetics and Cytogenetics Oncology and Haematology</italic>. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://atlasgeneticsoncology.org/Kprones/AlportLeiomyoID10134.html">online</ext-link>. 2008. Accessed 6-13-17.</mixed-citation>
            </ref>
            <ref id="alport.REF.byers">
              <mixed-citation publication-type="book">Byers PH. Disorders of collagen biosynthesis and structure. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> New York, NY: McGraw-Hill. Chap 205. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
            <ref id="alport.REF.pirson.1999.760">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pirson</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Making the diagnosis of Alport's syndrome.</article-title>
                <source>Kidney Int</source>
                <volume>56</volume>
                <fpage>760</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">10432421</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="alport.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="alport.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://experts.umn.edu/en/persons/clifford-kashtan(04043bb6-91b2-49d8-b16c-d9b2355c817a).html">Dr. Kashtan&#x02019;s website</ext-link>
          </p>
        </sec>
        <sec id="alport.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The author's work is supported by grants from the National Institutes of Health.</p>
        </sec>
        <sec id="alport.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>25 November 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 February 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 July 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>23 January 2008 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>8 January 2007 (cd) Revision: deletion/duplication analysis for <italic toggle="yes">COL4A5</italic> clinically available</p>
            </list-item>
            <list-item>
              <p>26 September 2005 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>29 December 2003 (ck) Revision: sequence analysis for COL4A5, COL4A3, COL4A4 clinically available; prenatal diagnosis available</p>
            </list-item>
            <list-item>
              <p>28 August 2003 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 August 2001 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>March 2001 (ck) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
